MedTrace Logo

Post-partum Depression, Breastfeeding Adherence and Fear in COVID-19

NCT04769700 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2023-10-02

No results posted yet for this study

Summary

This study aims to explore whether quarantine measures, social distancing and hospital containment policies among women giving birth during the COVID-19 pandemic enhanced psycho-emotional distress in the immediate postpartum period. The investigators tested for depression using the Edinburgh Postnatal Depression Scale (EPDS) in the first 6 postpartum months, and then used the Fear of COVID-19 Scale, measuring also the adherence and practices of breastfeeding according to WHO.

Conditions

  • Breast Feeding, Exclusive
  • Post Partum Depression
  • Covid19

Interventions

BEHAVIORAL

Edinburgh Postnatal Depression Scale

The Edinburgh Postnatal Depression Scale is a self-administered questionnaire made up of 10 items scored using a four-point Likert scale (0-3) designed to screen for symptoms of postpartum depression. Postpartum depression represents the end of a continuum of severity of symptoms. The present study used a cutoff point for depressive symptomatology risk of higher than 12.

BEHAVIORAL

Breast Feeding Adherence

This will be addressed according to the breastfeeding initiation practices according to the WHO.

BEHAVIORAL

Fear of Covid-19 Scale

The Fear of Covid-19 Scale is a questionnaire that evaluates fear of the global pandemic caused by the SARS-CoV-2. It consists of seven items, each with a five-point Likert scale of options. The participant is instructed to choose the option that best represents their perception about the statement presented. The maximum possible total is 35 points. The scale's authors indicate that the higher the score is, the higher is the level of the participants' fear of COVID-19.

Sponsors & Collaborators

  • Instituto Mexicano del Seguro Social

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04769700 on ClinicalTrials.gov